title: Subconjunctival bevacizumab in the impending recurrent pterygia.
abstract: The aim of this study is to evaluate the efficacy and safety of subconjunctival bevacizumab injection(s) in the treatment of impending recurrent pterygia. Twenty-three eyes of 23 patients who developed impending recurrence after pterygium surgery with conjunctival autografting and were treated with subconjunctival bevacizumab injection(s) (2.5 mg/0.1 mL) were included in the study. Anterior segment photographs were taken prior to and at 1 week, 1, 3 and 6 months after the injection, and at the end of the follow-up period. Image analysis was performed using an image processing and analysis software program. Recurrence rate and complications were recorded. The mean age and follow-up time of the patients were 51.2 ± 6.2 (31-60 years) and 16.8 ± 3.1 (12-22 months), respectively. The average number of injections was 2 ± 0.78 (1-3). Sixteen eyes required re-injection (two injections in nine eyes, three injections in seven eyes), due to progression of vascularization. There were significant differences between size percentage of lesions before injection and at 1 week, 1, 3 and 6 months after the injection (p < 0.05 for all). Corneal recurrence developed in only one patient and no ocular or systemic side-effects of bevacizumab were observed. Repeated injections of bevacizumab may help to prevent the high recurrence rate of residual impending pterygium, due to its adjuvant role in decreasing lesion size, especially in the first year after surgery.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Baskent University, Fevzi Cakmak Cad. 10. Sokak, 06490, Bahcelievler, Ankara, Turkey, sezinakca@gmail.com.
authors.forename: Sezin Akca
authors.initials: SA
authors.lastname: Bayar
authors.forename: Cem
authors.initials: C
authors.lastname: Kucukerdonmez
authors.forename: Ozlem
authors.initials: O
authors.lastname: Oner
authors.forename: Yonca A
authors.initials: YA
authors.lastname: Akova
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D003228:Conjunctiva / Q000098:blood supply; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D056965:Injections, Intraocular / Q000379:methods; D008297:Male; D008875:Middle Aged; D011625:Pterygium / Q000188:drug therapy* / Q000517:prevention & control; D012008:Recurrence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
references.citation: Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2545-52
references.pmid: 17525183
references.citation: Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1375-82
references.pmid: 19415316
references.citation: Cornea. 2001 Oct;20(7):738-42
references.pmid: 11588427
references.citation: Ophthalmology. 1997 Jun;104(6):974-85
references.pmid: 9186439
references.citation: Med Hypotheses. 2007;69(4):925-7
references.pmid: 17367957
references.citation: Br J Ophthalmol. 2007 Jun;91(6):804-7
references.pmid: 17179168
references.citation: Cornea. 2012 Feb;31(2):155-61
references.pmid: 22081150
references.citation: Cornea. 2003 Jul;22(5):473-7
references.pmid: 12827055
references.citation: Curr Eye Res. 2008 Jan;33(1):23-8
references.pmid: 18214740
references.citation: Cornea. 2011 Feb;30(2):127-9
references.pmid: 20885313
references.citation: Ophthalmology. 2006 Jul;113(7):1102-9
references.pmid: 16730066
references.citation: Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1577-9
references.pmid: 17458556
references.citation: Clin Exp Ophthalmol. 2007 Nov;35(8):745-8
references.pmid: 17997779
references.citation: Cornea. 2008 Apr;27(3):357-62
references.pmid: 18362668
references.citation: Br J Ophthalmol. 2009 Jul;93(7):864-5
references.pmid: 19553512
references.citation: Ophthalmology. 1994 Apr;101(4):755-8
references.pmid: 8152771
references.citation: Cornea. 2009 Jan;28(1):103-4
references.pmid: 19092418
references.citation: Ophthalmology. 2005 Jun;112(6):1023-30
references.pmid: 15885787
references.citation: Cornea. 2009 May;28(4):468-70
references.pmid: 19411971
references.citation: Cornea. 2008 Apr;27(3):349-52
references.pmid: 18362666
references.citation: Cornea. 2008 Feb;27(2):142-7
references.pmid: 18216566
references.citation: Acta Histochem. 1996 Apr;98(2):195-201
references.pmid: 8739304
references.citation: Am J Ophthalmol. 2008 Mar;145(3):424-431
references.pmid: 18207123
references.citation: Cornea. 2011 Nov;30(11):1219-22
references.pmid: 21955635
references.citation: Acta Ophthalmol. 2009 Sep;87(6):653-8
references.pmid: 19021596
references.citation: Ophthalmology. 1995 Dec;102(12):1949-52
references.pmid: 9098301
references.citation: Curr Eye Res. 2010 Jan;35(1):17-22
references.pmid: 20021250